Profil
Ronald Guido formerly worked at Pfizer Inc., as Senior Director, Veloxis Pharmaceuticals A, as Chief Compliance Officer from 2010 to 2016, IRX Therapeutics, Inc., as Executive VP-Regulatory Affairs & Quality Systems from 2017 to 2020, Travere Therapeutics, Inc., as Executive Vice President-Regulatory Affairs from 2013 to 2014, Eterna Therapeutics LLC, as Chief Development Officer from 2020 to 2021, and Eterna Therapeutics, Inc., as Chief Development Officer in 2021.
Mr. Guido received his undergraduate degree from Caldwell College, graduate degree from Polytechnic University, and graduate degree from Royal Hibernian Academy.
Anciens postes connus de Ronald Guido
| Sociétés | Poste | Fin |
|---|---|---|
| ETERNA THERAPEUTICS INC. | Chief Executive Officer | 16/04/2021 |
Eterna Therapeutics LLC
 Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The private company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | Chief Executive Officer | 25/03/2021 |
IRX Therapeutics, Inc.
 IRX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology IRX Therapeutics, Inc. provides pharmaceutical products. Its therapies are designed to target and restore the immune system in order to improve a patient's response to next-generation cancer vaccines and novel targeted therapeutics. The company was founded in 1994 and is headquartered in New York, NY. | General Counsel | 01/12/2020 |
| VELOXIS PHARMACEUTICALS A/S | Compliance Officer | 01/12/2016 |
| TRAVERE THERAPEUTICS, INC. | General Counsel | 01/06/2014 |
Formation de Ronald Guido
| Caldwell College | Undergraduate Degree |
| Royal Hibernian Academy | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| TRAVERE THERAPEUTICS, INC. | Health Technology |
| ETERNA THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
IRX Therapeutics, Inc.
IRX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology IRX Therapeutics, Inc. provides pharmaceutical products. Its therapies are designed to target and restore the immune system in order to improve a patient's response to next-generation cancer vaccines and novel targeted therapeutics. The company was founded in 1994 and is headquartered in New York, NY. | Health Technology |
| Polytechnic University | Consumer Services |
Eterna Therapeutics LLC
Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The private company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | Health Technology |
